MA53635A - Utilisation d'un inhibiteur de la cathepsine s contre la formation d'anticorps anti-médicament - Google Patents

Utilisation d'un inhibiteur de la cathepsine s contre la formation d'anticorps anti-médicament

Info

Publication number
MA53635A
MA53635A MA053635A MA53635A MA53635A MA 53635 A MA53635 A MA 53635A MA 053635 A MA053635 A MA 053635A MA 53635 A MA53635 A MA 53635A MA 53635 A MA53635 A MA 53635A
Authority
MA
Morocco
Prior art keywords
cathepsin
drug antibody
antibody formation
inhibitor against
against anti
Prior art date
Application number
MA053635A
Other languages
English (en)
Inventor
Syed Sohail Ahmed
Christian Klein
Fabrice Alain André Kolb
Young Marianne Manchester
De Almeida Bessa Juliana Mattos
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA53635A publication Critical patent/MA53635A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA053635A 2018-09-18 2019-09-18 Utilisation d'un inhibiteur de la cathepsine s contre la formation d'anticorps anti-médicament MA53635A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18195251 2018-09-18

Publications (1)

Publication Number Publication Date
MA53635A true MA53635A (fr) 2022-04-13

Family

ID=63787710

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053635A MA53635A (fr) 2018-09-18 2019-09-18 Utilisation d'un inhibiteur de la cathepsine s contre la formation d'anticorps anti-médicament

Country Status (15)

Country Link
US (1) US20210315863A1 (fr)
EP (1) EP3852880A1 (fr)
JP (1) JP7438198B2 (fr)
KR (1) KR20210061344A (fr)
CN (1) CN112839716A (fr)
AR (1) AR114732A1 (fr)
AU (1) AU2019344567A1 (fr)
CA (1) CA3112032A1 (fr)
CR (1) CR20210143A (fr)
IL (1) IL281444A (fr)
MA (1) MA53635A (fr)
MX (1) MX2021003127A (fr)
SG (1) SG11202102471XA (fr)
TW (1) TW202023542A (fr)
WO (1) WO2020058297A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018178055A1 (fr) * 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Molécule bispécifique de liaison à l'antigène pour un récepteur de co-stimulation du tnf
US20210332122A1 (en) * 2020-04-17 2021-10-28 Cedars-Sinai Medical Center Dysregulation of covid-19 receptor associated with ibd
WO2023245008A1 (fr) * 2022-06-13 2023-12-21 Genentech, Inc. Procédés de retardement ou de prévention de l'apparition de la maladie d'alzheimer à l'aide de crenezumab

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP2008501621A (ja) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
JP2007513972A (ja) * 2003-12-11 2007-05-31 アクシス・ファーマシューティカルズ・インコーポレイテッド 低分子治療剤または生物製剤の投与によって引き起こされる免疫応答を治療するためのカテプシンｓインヒビターの使用
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CA2625440C (fr) 2005-10-11 2023-06-13 Micromet Ag Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations
CN101466736B (zh) * 2006-04-10 2013-11-06 弗森抗体有限公司 靶向组织蛋白酶s的治疗
JP2010524851A (ja) 2007-04-03 2010-07-22 マイクロメット アーゲー 種間特異的結合ドメイン
SI2421826T1 (sl) 2009-04-20 2014-02-28 F. Hoffmann-La Roche Ag Derivati prolina kot inhibitorji katepsina
DK3489255T3 (da) 2011-02-10 2021-08-23 Roche Glycart Ag Muterede interleukin-2-polypeptider
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US8802665B2 (en) * 2012-02-17 2014-08-12 Genentech, Inc. Pyrrolidine derivatives
RU2018116402A (ru) 2015-10-07 2019-11-07 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела, четырехвалентные в отношении костимуляторного tnf-рецептора
CN115920030A (zh) * 2015-12-09 2023-04-07 豪夫迈·罗氏有限公司 Ii型抗cd20抗体用于降低抗药物抗体形成
KR20180111862A (ko) 2016-02-26 2018-10-11 에프. 호프만-라 로슈 아게 신규 피롤리딘 유도체
KR20200084006A (ko) 2017-11-01 2020-07-09 에프. 호프만-라 로슈 아게 표적화된 ox40 작용제를 사용하는 병용 요법

Also Published As

Publication number Publication date
AR114732A1 (es) 2020-10-07
TW202023542A (zh) 2020-07-01
IL281444A (en) 2021-04-29
US20210315863A1 (en) 2021-10-14
WO2020058297A1 (fr) 2020-03-26
CA3112032A1 (fr) 2020-03-26
AU2019344567A1 (en) 2021-03-25
CR20210143A (es) 2021-04-21
CN112839716A (zh) 2021-05-25
MX2021003127A (es) 2021-05-14
EP3852880A1 (fr) 2021-07-28
KR20210061344A (ko) 2021-05-27
JP2022501356A (ja) 2022-01-06
JP7438198B2 (ja) 2024-02-26
SG11202102471XA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
MA53635A (fr) Utilisation d'un inhibiteur de la cathepsine s contre la formation d'anticorps anti-médicament
MA51066A (fr) Inhibiteurs d'intégrine
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA51616A (fr) Inhibiteurs d'adn-pk
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA41350A (fr) Synthèse d'un inhibiteur de la tyrosine kinase de bruton
MA51223A (fr) Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine
MA46203A (fr) Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase
MA54399A (fr) Radioimmunoconjugués et polythérapie à base d'inhibiteur de point de contrôle
MA54052A (fr) Formulation d'anticorps
MA55801A (fr) Formes solides d'un inhibiteur de glyt1
MA54458A (fr) Formes cristallines et formes salines d'un inhibiteur de kinase
MA52152A (fr) Anticorps
MA51902A (fr) Schémas posologiques d'anticorps b7-h4
MA53328A (fr) Anticorps anti-siglec-5 et leurs procédés d'utilisation
MA56466A (fr) Anticorps anti-epha4
MA54526A (fr) NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta
MA52217A (fr) Variants d'anticorps anti-c-terminal
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
MA55705A (fr) Anticorps bispécifiques
MA50156A (fr) Variants d'anticorps
MA51207A (fr) Anticorps monoclonaux anti-trkb et leurs procédés d'utilisation
MA55809A (fr) Formulation d'anticorps anti-il-6
MA56394A (fr) Anticorps anti-angpt2